TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from HUTCHMED (China) ( (HK:0013) ) is now available.
HUTCHMED (China) Limited announced promising preclinical data for its investigational drug candidate, HMPL-A251, at an international conference. This drug, part of their ATTC platform, combines a potent PI3K/PIKK inhibitor with an anti-HER2 antibody to target cancer cells more effectively and with reduced toxicity compared to traditional therapies. The data showed strong antitumor activity and a favorable safety profile, positioning HMPL-A251 as a potential breakthrough in cancer treatment. HUTCHMED plans to initiate global clinical trials for HMPL-A251 by the end of 2025, aiming to redefine cancer treatment with more ATTC candidates in the pipeline.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
Average Trading Volume: 10,294,691
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$20.76B
See more insights into 0013 stock on TipRanks’ Stock Analysis page.